Sanofi : Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine - Form 6-K

(marketscreener.com) Positive Dupixent® Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine * Dupixent 300 mg weekly showed significant histological disease...https://www.marketscreener.com/quote/stock/SANOFI-4698/news/Sanofi-Positive-Dupixent-dupilumab-Phase-3-results-in-adults-and-adolescents-with-eosinophilic-42752271/?utm_medium=RSS&utm_content=20230117